CME Presentations

PN (Prurigo Nodularis)

Presentations

Speakers

  • Gil Yosipovitch, MD

    Gil Yosipovitch, MD

    Gil Yosipovitch, MD

    Professor and Stiefel Endowed Chair of Medical Dermatology

    Gil Yosipovitch, MD, is a Professor and Stiefel Endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at University of Miami (UM). He is the Director of the Miami Itch Center, which focuses on chronic itch as a disease state. Prior to joining UM, Dr. Yosipovitch was the Founding Chair of the Department of Dermatology at Temple University and directed the first translational, clinical and research center dedicated to the study of chronic itch in the US. He is the founder and past President of the International Forum for the Study of Itch and member of its board. In addition, he received one of the highest awards in dermatology, the Marion B. Sulzberger lectureship award, at the 2016 AAD meeting for his work on itch.

    Session Appearances

    Targeting Immune Pathways in Prurigo Nodularis: Hope to Enhance the Quality of Life for Patients

  • Shawn Kwatra, MD

    Shawn Kwatra, MD

    Shawn Kwatra, MD

    Associate Professor of Dermatology

    Shawn Kwatra, MD, is an Associate Professor of Dermatology at Johns Hopkins University School of Medicine in Baltimore and Director of the Johns Hopkins Itch Center. He specializes in medical dermatology and his areas of clinical expertise include chronic pruritus, prurigo nodularis, atopic dermatitis and dermatology for ethnic skin. Dr. Kwatra’s primary clinical and translational research interests comprise of the pathogenesis and treatment of chronic pruritus. He has been an author or co-author on over 200 publications in peer-reviewed international journals and is a member of several professional organizations such as the American Academy of Dermatology and the Society for Investigative Dermatology. Moreover, Dr. Kwatra is serving on the Board of Directors of the Skin of Color Society.

    Session Appearances

    Targeting Immune Pathways in Prurigo Nodularis: Hope to Enhance the Quality of Life for Patients

CME Information

Einstein Logo Montefiore Logo PQH Logo

Targeting Immune Pathways in Prurigo Nodularis: Hope to Enhance the Quality of Life for Patients

Presented by the Albert Einstein College of Medicine-Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC and in collaboration with the National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

TUITION

Complimentary

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and PlatformQ Health. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity: Wednesday, November 9, 2022 from 2:00 PM ET – 3:00 PM ET

Enduring Material
The enduring material will be available from November 9, 2022 to November 9, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Recognize the clinical symptoms of prurigo nodularis (PN)
  • Describe the burden of PN and its comorbidities on patients’ quality of life
  • Identify common comorbidities associated with PN, with a focus on those that share a common T2-driven inflammatory pathway
  • Evaluate the place of biologic agents targeting T2-inflammation in treatment optimization for PN

INTENDED AUDIENCE

This activity is intended for dermatologists and dermatology NPs and PAs.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™ participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All financial relationships listed for individuals have been mitigated.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Presenter Disclosures
Shawn Kwatra, MD
Associate Professor of Dermatology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine 		Consultant: Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutic, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Sanofi
Research Funding: Galderma, Incyte Corporation, Pfizer, Sanofi
Unlabeled/unapproved drugs will be referenced: Dupilumab, Nemolizumab, Vixarelimab, Nalbuphine, Celldex 0159, JAK Stats Inhibitors, Abrocitinib and Upacitinib
Gil Yosipovitch, MD
Professor
Stiefel Chair Medical Dermatology
Director Miami Itch Center
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery
U Miami Miller School of Medicine 		Consultant/Researcher: Abbvie, Arcutis, Celldex, Eli Lilly, Galderma, GSK, Kiniksa, Leo Pharma, Novartis, Pfizer, Trevi, Sanofi Regeneron
Unlabeled/unapproved drugs will be referenced: Dupilumab, Nemolizumab, Vixarelimab, Nalbuphine, Celldex 0159, JAK Stats Inhibitors, Abrocitinib and Upacitinib
Peer Reviewer Disclosures
Holly Kanavy, DO*
Associate Professor of Medicine, Director of Dermatopharmacology
Albert Einstein College of Medicine
Montefiore Medical Center 		Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
PlatformQ Health Education, LLC Disclosures
Carole Drexel, Medical Director* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Eve Wilson, Medical Director* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Jaimee Harris-Gold, Program Manager* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months

*Planner

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmunologyLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine-Montefiore Medical Center, ImmunologyLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.